Biotech Startups

Affinia Therapeutics develops genetically engineered adeno-associated virus (AAV) therapies for treating genetic diseases, focusing initially on cardiovascular and central nervous system conditions. The company uses AI and structural modeling to redesign viral delivery vectors for one-time-dose genetic medicines across rare and prevalent diseases.

7 investors

Agomab is a clinical-stage biopharmaceutical company developing disease-modifying therapies for fibro-inflammatory and fibrotic diseases with high unmet medical need. Its product candidates target established biological pathways using organ-restricted approaches to resolve fibro-inflammation and restore organ function.

7 investors

Aizon provides data solutions that help organizations analyze historical information and make informed decisions about future outcomes. The company operates in the data infrastructure and analytics space, serving enterprises across various industries.

7 investors

Nobell Foods develops cheese and other dairy products made from plant-derived dairy proteins, aiming to match the taste and price of conventional animal dairy. The company operates in the food technology and sustainable food sector.

7 investors

Alveus Therapeutics develops next-generation metabolic and obesity therapies, including its lead asset ALV-100 (in Phase 2) and a preclinical amylin pipeline of peptides, oral small molecules, and novel formats aimed at sustainable weight loss with better tolerability. The company uses human genetic data and clinical expertise to select drug targets in the obesity treatment landscape.

7 investors

Amatera develops crop genetics using cell culture, high-throughput automation, and machine learning to accelerate breeding of perennial crops such as coffee, grapevine, and bananas. It builds its own climate-resistant and disease-resistant varieties and partners with seed companies, agrifood firms, and research institutes to apply its CellTera technology for faster trait discovery.

7 investors

AminoChain builds decentralized infrastructure for biomedical research that connects biospecimens, participant consent, and research data through a network of biorepositories. The platform provides AI-powered search for biospecimens and participant management systems for prospective research studies.

7 investors

Ansa provides an enzymatic DNA synthesis platform that directly synthesizes complex sequences up to 900 bp and delivers constructs up to 50 kb without assembly-based methods. It serves scientists in gene and cell therapies, antibody discovery, CDMOs, and agrigenomics.

7 investors

Antheia uses a yeast-based biosynthesis and fermentation platform to manufacture Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) for essential medicines, offering an alternative to fragile agricultural sourcing. The company targets pharmaceutical supply chains, aiming to reduce drug shortages and improve reliability for medicines traditionally derived from plants.

7 investors

Anthology develops designer and hybrid genomes by decoding genomic "language" to engineer microbes that convert feedstocks such as sugars, plastics, and agricultural waste into products like chemicals, materials, and food ingredients. Its applications include producing functional proteins for healthy aging and GLP-1 companion foods, enzymes to improve animal health, and carbon-neutral bioproduction for a circular bioeconomy.

7 investors

Anthrogen develops Odyssey, a family of protein language models with 102 billion parameters designed for multi-objective protein design. The models provide an API for researchers and organizations in biotechnology and drug discovery.

7 investors

Arcellx develops CAR T-cell therapies that are individually designed for each patient, using the immune system to target and attack cancer. The company focuses on cell therapy for cancer treatment.

7 investors

Arda engineers plastic-free materials from spent grain sourced from brewers and distillers, using protein hierarchies and nontoxic chemistry. The company produces performance materials for fashion, beauty, automotive, and other industries while enabling circular supply chains.

7 investors

The company develops therapies for people with severe autoimmune diseases.

7 investors

Arsenal Biosciences is a clinical-stage company developing programmable cell therapies to treat solid tumors. The company uses computational and engineering approaches to create cancer medicines.

7 investors

Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases. The company focuses on long-acting therapeutic formulations to address endocrine and rare disease indications.

7 investors

Asher Bio is a biotechnology company developing targeted immunotherapies for cancer, autoimmune, and infectious diseases using a cis-targeting platform that selectively activates specific immune cell types. The approach aims to overcome the limitations of immunotherapies that act on multiple cell types.

7 investors

Atomic.ai combines machine learning and RNA biology to discover and develop RNA-based drugs. The company applies computational approaches to advance RNA therapeutics.

7 investors

Attivare develops AI-powered personalized immunotherapy treatments using a proprietary biomaterial scaffold (ATTImmune) that delivers immune agonists directly to tumor microenvironments, aiming to reduce systemic toxicity in cancer and infectious disease treatment.

7 investors

Attovia is a biotechnology company focused on drug development and clinical strategy, aiming to bring treatments to patients where none exist and create next-generation therapeutic options. Its team includes a leadership team, board of directors, and scientific advisors experienced in drug development and company building.

7 investors

AuX Labs uses precision fermentation to produce recombinant milk proteins, starting with casein, that replicate the functional performance of dairy without animals. It sells these proteins to food manufacturers, CPG brands, and food-service operators for use in dairy products.

7 investors

Axi.om uses agentic intelligence and AI to predict, explain, and fix drug toxicity early in development by leveraging the largest experimental-to-clinical dataset of profiled molecules linked to human clinical outcomes.

7 investors

Basepair is a SaaS bioinformatics platform that provisions in a customer's own AWS account to store and analyze genomic and next-generation sequencing (NGS) data without moving it, offering point-and-click and API-driven workflows plus interactive visualization. It serves healthcare and life-science research teams, including bench scientists and bioinformaticians, with prebuilt pipelines for genomics, transcriptomics, and epigenomics.

7 investors

Basepaws offers a DNA testing service for cats that analyzes genetic breed similarity and provides breed breakdown reports for mixed-breed and domestic cats. The test compares a cat's genetic sequence to known breed databases rather than confirming pedigree status.

7 investors